Want to see HK:2561 full AI Analyst Report?
Top Page
VISEN Pharmaceuticals
(2561)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$19.00
▼(-43.59% Downside)
Action:Reiterated
Date:07/08/26
The score is primarily held down by weak financial performance, with persistent losses and significant negative operating/free cash flow (cash burn) despite only moderate leverage. Technicals add further pressure as the stock trades below key moving averages with soft momentum. Valuation contributes limited support because the negative P/E reflects ongoing losses and no dividend yield is available.
Positive Factors
Balance-sheet flexibility
Modest leverage and historically very low debt (2022–2024) provide structural financial flexibility. This reduces near-term solvency risk, giving management time to execute clinical programs or seek non-dilutive funding, supporting the firm’s ability to pursue long-term value-creating milestones.
Negative Factors
Revenue decline and persistent losses
A sharp revenue decline alongside recurring negative EBIT and net income signals weak demand or commercialization setbacks. Over the medium term, shrinking top-line undermines scalability and worsens operating leverage, reducing the company's ability to self-fund development or sustain growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet flexibility
Modest leverage and historically very low debt (2022–2024) provide structural financial flexibility. This reduces near-term solvency risk, giving management time to execute clinical programs or seek non-dilutive funding, supporting the firm’s ability to pursue long-term value-creating milestones.
Read all positive factors
VISEN Pharmaceuticals (2561) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.23B
Dividend YieldN/A
Average Volume (3M)19.58K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees82
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-2.44
Shares Outstanding113,926,865
10 Day Avg. Volume10,610
30 Day Avg. Volume19,576
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)4.01
Price to Sales (P/S)19001.90
P/FCF Ratio-6.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.12
Revenue Forecast (FY)HK$67.73M
VISEN Pharmaceuticals Business Overview & Revenue Model
Company Description
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-...
How the Company Makes Money
null...
VISEN Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
14
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 160.73K | 2.78M | -1.67M | -2.30M |
| Gross Profit | 18.51K | 2.78M | -1.67M | -2.30M |
| EBITDA | -249.16M | -177.62M | -242.26M | -280.95M |
| Net Income | -246.86M | -182.24M | -249.57M | -288.97M |
Balance Sheet | ||||
| Total Assets | 977.72M | 293.82M | 443.80M | 741.27M |
| Cash, Cash Equivalents and Short-Term Investments | 632.92M | 203.59M | 347.78M | 626.46M |
| Total Debt | 177.06M | 2.36M | 3.65M | 6.00M |
| Total Liabilities | 215.34M | 52.55M | 52.92M | 88.67M |
| Stockholders Equity | 762.38M | 241.28M | 390.88M | 652.61M |
Cash Flow | ||||
| Free Cash Flow | -450.16M | -140.97M | -271.83M | -248.31M |
| Operating Cash Flow | -447.58M | -140.86M | -271.31M | -246.55M |
| Investing Cash Flow | 6.67M | -117.00K | -520.00K | -1.77M |
| Financing Cash Flow | 870.00M | -3.09M | -6.95M | -7.95M |
VISEN Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$202.18B | 25.40 | 18.26% | 1.32% | 24.97% | 43.23% | |
61 Neutral | HK$2.34B | -20.51 | -10.61% | ― | 83.49% | -110.21% | |
60 Neutral | HK$18.35B | 141.03 | 1.43% | ― | -8.55% | -96.20% | |
59 Neutral | HK$15.26B | 67.91 | 1.67% | 3.93% | 3.10% | -46.64% | |
57 Neutral | HK$12.36B | 322.79 | 0.82% | 1.31% | 38.42% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
42 Neutral | HK$2.23B | -6.75 | -31.33% | ― | ― | ― |
* General Sector Average
HK:2561
VISEN Pharmaceuticals
19.28
-25.00
-56.46%
HK:0013
HUTCHMED (China)
20.46
-7.22
-26.08%
HK:2552
Hua Medicine
2.45
-1.87
-43.29%
HK:9989
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
4.23
-1.44
-25.47%
HK:3692
Hansoh Pharmaceutical Group Company Limited
32.72
-3.07
-8.58%
HK:6185
CanSino Biologics, Inc. Class H
25.80
-29.00
-52.92%
VISEN Pharmaceuticals Corporate Events
VISEN Pharmaceuticals Grants Performance-Linked Share Awards to Key Staff
Jul 20, 2026
VISEN Pharmaceuticals has granted 514,068 share awards to 19 senior managers and employees under its existing share award scheme, with no purchase price payable by the grantees. The awards, tied to the company’s Hong Kong-listed shares, are ...
VISEN Pharmaceuticals Shareholders Approve All AGM Resolutions and Expand Board
Jun 26, 2026
VISEN Pharmaceuticals reported that all ordinary resolutions at its 26 June 2026 annual general meeting were duly passed by shareholders via poll voting, including approval of the 2025 audited financial statements and the re-election of key execut...
VISEN Pharmaceuticals Clarifies Board Structure and Committee Roles
Jun 26, 2026
VISEN Pharmaceuticals has published an updated list of its board of directors and detailed the roles and functions they hold within the company. The announcement confirms the composition of the board, including one executive director, multiple non...
VISEN Pharmaceuticals Adds New Director Appointments to AGM Agenda
Jun 17, 2026
VISEN Pharmaceuticals has issued a supplemental notice to its previously announced annual general meeting, confirming that the AGM will still take place in Shanghai on June 26, 2026, at 10:00 a.m. local time. The company is adding three new ordina...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.